Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 92.5%

Neg 92.5% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Equal-Weight and lowers the price target from $30 to $19.